Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9940095 | 0.93 | TSHR (0.36) | TSHRALDH1A1 | |
| Bromide SCHEMBL28977646 | 0.87 | PDE4A (0.31) | — | |
| SCHEMBL329331 | 0.84 | GBA1 (0.32) | TSHRALDH1A1 | |
| SCHEMBL5287172 | 0.80 | GBA1 (0.31) | — | |
| SCHEMBL5286518 | 0.80 | EBP (0.36) | TSHRALDH1A1 | |
| SCHEMBL5296586 | 0.78 | EBP (0.39) | TSHRALDH1A1 | |
| SCHEMBL5291657 | 0.78 | EBP (0.39) | TSHRALDH1A1 | |
| SCHEMBL5298395 | 0.78 | EBP (0.39) | TSHRALDH1A1 | |
| SCHEMBL5288291 | 0.78 | EBP (0.39) | TSHRALDH1A1 | |
| SCHEMBL5284107 | 0.78 | EBP (0.39) | TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10421769-B2 | Anticancer property studies of chiral palladium N-heterocyclic carbene complexes and process for preparation thereof | India Institute of Technology Bombay (IN) | 2019-09-24 | — | — | US | disclosed |
| US-20180194789-A1 | ANTICANCER PROPERTY STUDIES OF CHIRAL PALLADIUM N-HETEROCYCLIC CARBENE COMPLEXES AND PROCESS FOR PREPARATION THEREOF | India Institute of Technology Bombay (IN) | 2018-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10421769-B2 | Anticancer property studies of chiral palladium N-heterocyclic carbene complexes and process for preparation thereof | PDCD1LG2, PDCD1, ODC1 | TSHR 1873/4885ALDH1A1 408/4885 |
| US-20180194789-A1 | ANTICANCER PROPERTY STUDIES OF CHIRAL PALLADIUM N-HETEROCYCLIC CARBENE COMPLEXES AND PROCESS FOR PREPARATION THEREOF | PDCD1LG2, PDCD1, MCL1 | TSHR 1845/4885ALDH1A1 547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.